Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Alabama Oncology

Neither a doctor nor a teaching hospital

Research payments

$367,917

104 payments

Through program year 2025, Alabama Oncology is reported as receiving $367,917 in research payments, across 104 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $36,489 6
2024 Research $7,237 3
2023 Research $34,341 7
2022 Research $23,791 5
2021 Research $161,950 73
2020 Research $62,021 5
2019 Research $42,088 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $86,194 11 payments
  2. AstraZeneca UK Limited $82,477 5 payments
  3. Pfizer Inc. $58,514 8 payments
  4. TG Therapeutics, Inc. $44,955 60 payments
  5. Amgen Inc. $22,033 3 payments
  6. AstraZeneca Pharmaceuticals LP $19,700 6 payments
  7. Puma Biotechnology, Inc. $19,300 2 payments
  8. G1 Therapeutics, Inc. $16,490 1 payment
  9. Genentech, Inc. $13,500 4 payments
  10. Jazz Pharmaceuticals Inc. $4,200 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Phase III Nivo Ipi vs Placebo in Adjuvant RCC $67,062 3 payments
  2. Polaris Palbociclib in Hormone Receptor Positive Advanced Breast Cancer A Prospective Multicenter Noninterventional Study $41,725 4 payments
  3. This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR and Rad3 related protein kinase and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 in second or third line setting in patients with Triple negative breast cancer prospectively stratified by presence absence of qualifying tumour mutation in genes involved in the homologous recombination repair pathway $28,229 3 payments
  4. SERENA-2 A Randomised Open-Label Parallel-Group Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer $27,582 1 payment
  5. SERENA-2 A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer $26,666 1 payment
  6. AMG 510 Ph2 First Line Monotherapy NSCLC. $20,124 2 payments
  7. Ali-1201 $18,700 1 payment
  8. A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) $16,490 1 payment
  9. An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 $15,990 22 payments
  10. UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkins Lymphoma $14,961 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record